Thymalin

Thymalin is a thymus-derived peptide MIXTURE from calf/bovine tissue, not a single molecule. Thymosin Alpha-1 is a single synthetic 28-amino-acid peptide approved in 30+ countries for hepatitis B/C and as a vaccine adjuvant. Thymulin is a different 9-amino-acid zinc-binding peptide (facteur thymique serique). Thymalin overlaps with Thymosin Alpha-1 but adds other peptides; the Russian evidence is strongest for the mixture applied to general immune restoration and aging.

It is more legitimate than the Western literature reflects and less rigorously verified than Western regulatory standards require, both at once. The Khavinson group has published over 200 papers across 40+ years at a legitimate academic institute, and Thymalin is a registered pharmaceutical used in millions of patient-doses. However, blinding, placebo control, randomization, and pre-registered endpoints are not consistently reported, and the grander claims have not been independently replicated in Western-rigor trials. The honest position is agnostic: too substantial to dismiss, too methodologically gap-laden to treat as proven.

It is not FDA-approved and not available through US pharmacy channels. The Russian pharmaceutical product is not exported to the US under any regulated channel. Thymalin is available in the US research-chemical peptide market for research purposes only. Possession and small-quantity personal importation are generally not enforced, but there is no FDA oversight of manufacturing quality, so buyers should favor suppliers with documented chain of custody, COA/HPLC data, and endotoxin testing.

The Russian clinical standard is 10 mg/day intramuscular or subcutaneous for 10 consecutive days (a 'course'), 1-2 times per year, often one course in autumn and one in late winter. First-timers may start at 5 mg/day. Intensive protocols use up to 3-4 courses per year at 10-15 mg/day. The discrete 10-day-course structure is important; continuous daily dosing is NOT the evidence-supported protocol.

The most evidence-supported combination is Thymalin + Epithalon, the canonical Khavinson stack from the Russian mortality trials, given as sequential 10-day courses separated by 2-4 weeks and repeated biannually. Reasonable additions include vitamin D and zinc (both support thymic peptide activity). Avoid combining with immunosuppressive medications or active checkpoint inhibitor immunotherapy.

Track subjective markers (frequency of minor infections, energy, exercise recovery, wound healing) and objective ones (CBC with lymphocyte differential and T-cell subset panels before a course, immediately after, and ~3 months later). Comparing infection frequency in the 6 months after a course to the 6 months before is a meaningful endpoint. If nothing changes after 2 full cycles (roughly 6-12 months), reconsider whether it adds value.

There is emerging, evidence-informed (not evidence-proven) interest. Russian groups reported improved recovery and T-cell restoration in COVID-19 patients, though trials were generally not placebo-controlled. A common approach is a single 10-day course at 10 mg/day starting 2-4 weeks after acute illness resolution, evaluated over 1-3 months. Rest, pacing, vitamin D, sleep, and nutrition likely matter more than the peptide itself for recovery.

This is genuinely uncertain and context-dependent, so use in autoimmune disease should only occur under rheumatology or immunology supervision. Its T-cell-normalizing effects could theoretically help (restoring Treg function, reducing senescent T-cells) or harm (increasing pathogenic activated T-cells). Avoid during active flares, do not combine with biological DMARDs without guidance, and avoid in patients on immunosuppression.